BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $34 from $32 and keeps a Buy rating on the shares following FDA approval for mitapivat to make it the only drug approved in both transfusion-dependent and non-transfusion-dependent alpha- or beta- thalassemia. The REMS and black box for hepatocellular injury were in line with the firm’s expectations and BofA doesn’t expect this to impact uptake, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients
- Agios Pharmaceuticals trading halted, news pending
- Agios Pharma: Hold Rating Amid Regulatory Uncertainty and Gradual Market Launch
- Anticipated FDA Approval of Agios Pharma’s Pyrukynd Expected to Boost Stock Value
- Morning Movers: Confluent surges following deal to be bought by IBM